Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
11 authors.
Angel Quiroz-BolañosDepartamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 950 Sierra Mojada St., Independencia, Guadalajara 44340, Jalisco, Mexico.
Antonio Quintero-RamosDepartamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 950 Sierra Mojada St., Independencia, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0001-5963-9712
Juliana Marisol Godínez-RubíDepartamento de Microbiología y Patología, Laboratorio de Patología Diagnóstica e Inmunohistoquímica (LAPADI), Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 950 Sierra Mojada St., Independencia, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0002-6779-1017
Ramon Franco-TopeteDepartamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 950 Sierra Mojada St., Independencia, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0002-9080-6192
Porfirio Gutiérrez GonzálezDepartamento de Matemáticas, Centro Universitario de Ciencias Exactas e Ingenierías, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.
Bricia M Gutiérrez-ZepedaDoctorado en Genética Humana, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0002-9239-665X
Denisse S Becerra-LoaizaDoctorado en Genética Humana, Departamento de Biología Molecular y Genómica, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0003-1251-3383
Antonio TopeteDepartamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 950 Sierra Mojada St., Independencia, Guadalajara 44340, Jalisco, Mexico.
Cesar de Loera-RodriguezDepartamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 950 Sierra Mojada St., Independencia, Guadalajara 44340, Jalisco, Mexico.
Alicia Del Toro-ArreolaDepartamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 950 Sierra Mojada St., Independencia, Guadalajara 44340, Jalisco, Mexico.
Adrián Daneri-NavarroDepartamento de Fisiología, Centro Universitario de Ciencias de la Salud, Universidad de Guadalajara, 950 Sierra Mojada St., Independencia, Guadalajara 44340, Jalisco, Mexico.ORCID 0000-0002-8206-749X
Funding
Consejo Estatal de Ciencia y Tecnología 8176-2019, 10259-2022 and 2021-9887 2022
6 · The paper itself
Abstract
Immunotherapy with antibodies targeting immune checkpoints, in combination with standard therapies, is one of the areas with the most significant clinical research, particularly in aggressive tumors such as triple-negative breast cancer, where there have been relevant advances with antibodies against PD-1/PD-L1. However, it is essential to define the biological and molecular factors that influence survival and response to immunotherapy, as other immune control points, such as CTLA-4, TIM-3, LAG-3, TIGIT, and VISTA, also play a role. The immune checkpoints were studied by microarrays and immunohistochemistry in 243 samples from patients with breast cancer, according to the molecular subtype. Significant differences in PD-1, PL-1, CTLA-4, and TIGIT expression were observed between triple-negative and Her-2 tumors compared to Luminal A and Luminal B tumors. No differences in VISTA expression were observed between the different molecular subtypes. Patients with high-grade tumors showed higher PD-1, PD-L1, LAG-3, and VISTA expression than low and intermediate-grade tumors. We observed a significant difference in PD-L1/TIGIT co-expression in tumor-infiltrating cells from patients with triple-negative tumors compared to patients with Luminal A, Luminal B, and Her2+ tumors. These results are relevant in the context of clinical application.
Indexed as
Breast NeoplasmsImmune Checkpoint ProteinsAdultAgedB7-H1 AntigenBiomarkers, TumorErb-b2 Receptor Tyrosine KinasesFemaleHumansLymphocyte Activation Gene 3 ProteinMiddle AgedProgrammed Cell Death 1 ReceptorReceptors, ImmunologicRetrospective StudiesTriple Negative Breast NeoplasmsB7-H1 AntigenBiomarkers, TumorCD274 protein, humanErb-b2 Receptor Tyrosine KinasesImmune Checkpoint ProteinsLag3 protein, humanLymphocyte Activation Gene 3 ProteinPDCD1 protein, humanProgrammed Cell Death 1 ReceptorReceptors, ImmunologicTIGIT protein, humanimmune-checkpoint expressionoverall survivaltriple-negative breast cancer
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Immune-Checkpoint Expression in Breast Cancer Patients: Clinicopathological Implications: A Retrospective Case Series Study. · full record | OpenQuestion